Market Snapshot – Heidelberg Pharma and Peer Performance
On Tuesday, October 20, 2026, Heidelberg Pharma (ticker HPHA.DE) closed its trading day unchanged, trading flat at 0 % over the 24‑hour period that concluded at 10:21 PM Central European Time. The stock price hovered around EUR 2.22, a level that has become familiar to investors on the Xetra exchange.
Trading Metrics
- Current Market Capitalisation: EUR 103.4 million
- Shares Outstanding: 46.8 million
- Volume (last 24 h): EUR 2.2 million
- 52‑Week High: EUR 3.34 (recorded 01 Sep 2026)
- 52‑Week Low: EUR 2.15 (recorded 16 Oct 2026)
- 200‑Day Simple Moving Average: EUR 2.72
- Month‑to‑Date Performance: -11.65 %
These figures paint a picture of a company that has experienced a notable decline since the close of the previous month, yet remains within a relatively narrow price band defined by its recent historical peaks and troughs. The stock’s proximity to its 200‑day moving average suggests a period of consolidation, where short‑term volatility is balanced against longer‑term trends.
Peer Comparison – 24‑Hour Performance
The surrounding sector offers a mixed view of performance, with several peers showing divergent movements that shed light on the broader market sentiment:
| Company | Ticker | 24‑H Performance | Current Price | Market Cap | Notes |
|---|---|---|---|---|---|
| Knaus Tabbert | KTA.DE | -2.76 % | EUR 9.42 | EUR 98.9 million | Slight decline |
| Lewag | KGR.F | 0 % | EUR 24.00 | EUR 114 million | Stable |
| Scp Standard Capital Partner | VAD.DE | -17.9 % | EUR 2.22 | EUR 109.3 million | Significant drop |
| Mph Health Care Konv | 93M1.DE | +1.06 % | EUR 28.30 | EUR 122.5 million | Modest gain, P/E = 2.52 |
| Anbio Biotechnology | NNNN | +4.47 % | USD 3.73 | USD 137.4 million | Strong rally, P/E = 86.61 |
While Heidelberg Pharma’s flat performance contrasts with the modest gains seen by Mph Health Care Konv and Anbio Biotechnology, it aligns more closely with the steadiness of Lewag and the pronounced decline of Scp Standard Capital Partner. The variance among these stocks underscores the heterogeneity within the biopharmaceutical and related sectors, where factors such as pipeline progress, regulatory approvals, and market sentiment can drive divergent price actions.
Company Overview
Heidelberg Pharma AG is a German‑based biopharmaceutical enterprise that focuses on developing and commercialising innovative cancer therapies. Its research portfolio extends to pharmacology, drug metabolism, pharmacokinetics, and molecular biology, with a particular emphasis on oncology and inflammatory diseases. Founded in the early 2000s, the company went public on November 13, 2006, listing its shares on the Xetra stock exchange. Heidelberg Pharma continues to serve patients and healthcare professionals across Germany, maintaining a robust research pipeline aimed at addressing unmet medical needs.
For further details, investors and stakeholders can visit the company’s website at www.heidelberg-pharma.com .
